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Introduction 
 
The emergence and spread of multi-resistant pathogenic strains declined the number of clinically 
available antibiotics and caused a serious public health problem. Therefore, the development of novel 
antimicrobial agents with effective treatment of the drug-resistant pathogens is needed to combat this 
situation. Our lab also worked on the discovery of novel antimicrobial compounds and isolated a novel 
lipopeptide antibiotic named as kaikosin E using silkworm infection model. Kaikosin E exhibits good 
antibiotic traits such as obvious therapeutic effect in mouse infection model with low toxicity and rapid 
bactericidal activity compared with other clinically used antibiotics. Cell lysis also occurred after 
treatment with kaikosin E. Adding kaikosin E to Staphylococcus aureus rapidly dissipated membrane 
potential. Based on these findings, disruption of membrane is one proposed mechanism of action for 
kaikosin E. However, the details are still unknown. In searching of target for kaikosin E, fni or menA 
gene mutation was found in kaikosin E resistant mutant. Both genes are involved in menaquinone 
biosynthesis pathway. Furthermore mixing kaikosin E with menaquinone caused complex precipitation 
in water. These results guide me to focus on the importance of menaquinone for uncovering kaikosin E 
mechanism. In addition, a recent study showed the antimicrobial activity of kaikosin E against S.aureus 
was enhanced by addition of serum. This finding suggested that an enhancing factor for antimicrobial 
activity of kaikosin E exists in serum. Therefore, identification of this factor may facilitate knowing the 
interaction of kaikosin E with its target and provide information for improving the therapeutic activity of 
kaikosin E. In this study, I intend to further elucidate the antimicrobial mechanism of kaikosin E through 
the identification of the role of menaquinone in membrane damage and identification of the serum 
factor responsible for enhancing antimicrobial activity of kaikosin E. 
 
Results 
 
1. Identification of menaquinone as a target 
In view menaquinone existed in cell membrane and kaikosin E had membrane damaging activity, 
identification of the role of menaquinone in 
membrane damage may facilitate elucidation 
of kaikosin E mechanism. To test the role of 
menaquinone on kaikosin E-mediated 
membrane damage effect ，  calcein-
encapsulated liposome was prepared and 
used for membrane leakage assay. Kaikosin E 
significantly caused leakage of liposome 
containing menaquinone (MK) compared with 
liposome without menaquinone (Figure 1), Figure 1. Membrane leakage assay. Values for 100% calcein 
release were obtained using Triton X-100.,P<0.01;,P<0.001. 
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whereas daptomycin showed no significant difference on leakage of liposome with or without 
menaquinone. Hence, the existence	   of menaquinone stimulated membrane damaging activity of 
kaikosin E. On the other hand, kaikosin E had no hemolytic effect on sheep red blood cells, suggesting 
that this membrane damaging effect is specific to bacteria. To further confirm the interaction of 
kaikosin E with menaquinone, isothermal titration calorimetry (ITC) assay was conducted for 
characterization of binding affinity between them. ITC results showed kaikosin E binds with 
menaquinone at a molar ratio of 1:1 with an affinity constant (Ka) of 2.2±0.4×105M-1. These results 
suggest kaikosin E binds with menaquinone in cell membrane and induces membrane damage. 
 
2. Identification of a serum factor enhancing antimicrobial activity of kaikosin E 
Antimicrobial activity of kaikosin E against S. aureus was enhanced more than 10-fold in the presence 
of bovine calf serum. This enhancement effect on antimicrobial activity of kaikosin E was also detected 
in human plasma and other 
mammalian serum. 
Considering the significant 
enhancement effect of 
serum on kaikosin E activity, 
I assume some factors in 
serum act as enhancers. 
Thus I tried to purify the 
enhancing factor from 
serum. One unit of enhancing activity is defined as the minimum amount of active factor which can 
inhibit bacterial growth in the presence of 1µg/ml kaikosin E. Enhancing factor in serum was purified 
with ethanol extraction followed by octadecyl silica (ODS) column chromatography with 190-fold 
increase in specific activity (Table 1). ODS column fraction lost 97% of enhancing activity after trypsin 
treatment. This result suggested that a protein in serum is responsible for enhancing antimicrobial 
activity of kaikosin E. To further identify the active protein, fractions from ODS column were analyzed 
by SDS polyacrylamide gel electrophoresis. Twenty-four kDa protein band was observed in active 
fractions (Figure 2). These fractions were further analyzed by HPLC using size exclusion column, and 
the band intensity of 24 kDa protein from each fraction correlated with its enhancing activity. Peptide 
mass fingerprinting analysis revealed the 24 kDa protein was matched with the sequence of 
apolipoprotein A-I (Apo A-I). Antimicrobial activity of kaikosin E was enhanced 16-fold in the presence 
of 90 µg/ml of human recombinant apolipoprotein A-I, which is equivalent to 10% serum. 
Apolipoprotein A-I itself had no antimicrobial activity against S. aureus (Table 2). These results 
suggested apolipoprotein A-I is one serum factor responsible for enhancing antimicrobial activity of 
kaikosin E. The mechanism of apolipoprotein A-I mediated enhancement on antimicrobial activity of 
kaikosin E needs to be elucidated. 
!
Table&1.&Puriﬁca/on&of&a&serum&factor&enhancing&an/microbial&ac/vity&of&kaikosin&E
Fraction Weight 
(mg) 
Total activity 
(Units) 
Specific activity 
(U/mg) 
Yield 
(%) 
Purification 
(fold) 
.Serum 96 640 7 100 1 
.60%EtOH extract 18 2600 140 406 20 
.ODS Fr.1 
       Fr.2 
       Fr.3 
       Fr.4 
16 
0.2 
0.8 
0.5 
<20 
<20 
<20 
640 
¯ 
¯ 
¯ 
      1300 
¯ 
¯ 
¯ 
100 
¯ 
¯ 
¯ 
190 
       Fr.5 0.1 80  800 13 110 
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Table 2. Effect of serum on antimicrobial activity of kaikosin E 
Medium MIC(µg/ml)  
Mueller-Hinton broth 4 
+ Serum(10%) 0.25 
+ Human recombinant apolipoprotein A-I(90 µg/ml) 0.13 !  
 
3. Interaction of apolipoprotein A-I with kaikosin E and 
menaquinone 
Menaquinone was reported to interact with high-density 
lipoprotein. Apolipoprotein A-I is known as the major 
component of high-density lipoprotein in plasma. Hence I proposed apolipoprotein A-I enhances 
antimicrobial activity of kaikosin E through interaction with menaquinone and kaikosin E.  To test this 
hypothesis, interaction assay among apolipoprotein, menaquinone and kaikosin E was performed. 
After mixing kaikosin E and menaquinone at a molar ratio of 1:1 and centrifugation, yellow pellet was 
shown in the bottom of the tube. When mixing apolipoprotein A-I, kaikosin E and menaquinone, 
organge pellet was shown in the mixing solution 
whereas apolipoprotein A-I solution itself was 
transparent. Hence, I speculate that apolipoprotein A-I 
interacts with the binding complex of kaikosin E with 
menaquinone and changes the color of pellet. To check 
this possibility, the precipitate from mixing apolipoprotein 
A-I, kaikosin E and menaquinone solution was applied 
into SDS-PAGE analysis. Apolipoprotein A-I band was 
detected in the precipitate sample from mixing 
apolipoprotein A-I, kaikosin E and menaquinone solution 
(Figure 3). These results suggested apolipoprotein A-I 
interacts with kaikosin E and menaquinone. 
Apolipoprotein A-I may enhance the antimicrobial activity 
of kaikosin E through interaction with kaikosin E and menaquinone. 
 
Discussion 
 
This study demonstrates kaikosin E binds with menaquinone in cell membrane and induces membrane 
damage. To my knowledge, this is the first report that menaquinone is identified as a target of antibiotic. 
Menaquinone is an essential component of bacterial electron transport chain. In contrast, ubiquinone is 
a coenzyme utilized in human electron transport chain. The finding that kaikosin E specifically binds 
with menaquinone not ubiquinone explains that membrane damage effect induced by kaikosin E is 
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specific to bacteria. Therefore, menaquinone can be used as a potential target for the development of 
novel antibacterial drugs. 
 
In this study, I also identified apolipoprotein A-I as a serum factor, which is responsible for enhancing 
antimicrobial activity of kaikosin E against S. aureus. This finding explains the fact that kaikosin E has 
good therapeutic activity compared with vancomycin in mouse infection model, whereas the 
antimicrobial activity of kaikosin E detected in culture medium is lower than that of vancomycin. 
Therefore, the enhanced antimicrobial activity of kaikosin E in vivo may be due to the existence of 
apolipoprotein A-I in serum. This finding provides evidence for kaikosin E to be successful use in future 
clinical situation. Study on the interaction among apolipoprotein A-I, kaikosin E and menaquinone 
showed that apolipoprotein A-I interacts with the binding complex between kaikosin E and 
menaquinone. Therefore, apolipoprotein A-I may enhance antimicrobial activity of kaikosin E through 
interaction with the binding complex of kaikosin E and menaquinone. 
